Ann: Imugene Presents New PD1-Vaxx Data at the 2022 WCLC, page-36

Just something to keep in mind re immunogenicity.

At the higher dose 100micrograms, we have an increase in immunogenicity. As LC says in the announcement "I am encouraged that we are seeing positive signals with correlative biomarker data at such an early stage of our PD1-Vaxx Phase I trial"

But just notice the graph... at higher levels we get the immunogenicity... good stuff. Not so much at lower levels 10 and the 50.



We want this immunogenicity as it's really great for combo therapy.

The downside is this immune response needs to be controlled. In the abstract it said

"One patient experienced an immune related phenominitis and discontinued from study".

In the results this morning it says there were two events of immune related penomitis. Both patients removed.

In the conclusion it says...the potential for immune related adverse events requires evaluation, but also generally safe and well tolerated.


However it is good they are saying, they will evaluate patients for the next round phase 1B. Moreover this next study will include naive patients who have not had previous treatment, will be very different.